Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Invesco Ltd.

Invesco Ltd. cut its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 87.2% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 359,143 shares of the company’s stock after selling 2,439,721 shares during the period. Invesco Ltd. owned approximately 0.76% of Amphastar Pharmaceuticals worth $10,412,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC lifted its position in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after acquiring an additional 520 shares in the last quarter. IFP Advisors Inc acquired a new position in Amphastar Pharmaceuticals during the 1st quarter worth approximately $34,000. GF Fund Management CO. LTD. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $38,000. GAMMA Investing LLC lifted its position in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after acquiring an additional 348 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMPH has been the topic of several recent research reports. JPMorgan Chase & Co. reissued a “neutral” rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Wells Fargo & Company cut their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Tuesday, August 12th. Finally, Piper Sandler cut their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.50.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $30.50 on Monday. The business’s 50 day moving average is $24.10 and its two-hundred day moving average is $25.77. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.39 and a 52-week high of $53.96. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 11.42 and a beta of 0.76. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.